Our values, the people behind the portfolio, and where we are going.
Go to Why EmeraNovaEmeraNova has multiple clinical trials designed, and in process, to demonstrate the efficacy and safety of its Cellular, Acellular, and Matrix-like Products (CAMPs), as well as Microlyte™, cureVision™, terraplasma™, and APIS®.
A multicenter, prospective, randomized controlled study assessing the efficacy of human placental membrane products, specifically Membrane Wrap™ and Tri-Membrane Wrap™, combined with standard of care (SOC) versus SOC alone in the management of nonhealing DFUs and VLUs.
A multicenter hybrid platform comparative study of a prospective cohort treated with Tri-Membrane Wrap™ or Membrane Wrap - Lite™ against a matched retrospective control cohort of patients with hard-to-heal DFUs and VLUs. Enrollment has finished and the statistics are being compiled.
A comparative, prospective study comparing Moleculight and tissue biopsies to the fluorescent imaging bacteria detection capabilities of the cureVision device. An observational study using Microlyte™ PainGuard® on the biopsy site is included in this trial.
An identical study to CAMP RWE using three different products — Membrane Wrap - Hydro™, Microlyte™ and APIS® — which allows all three to be studied simultaneously, across DFU and VLU cohorts.
A retrospective study on pressure ulcers demonstrating improved healing outcomes over standard of care using Membrane Wrap™. International Journal of Tissue Repair.
doi.org/10.63676/d2k9hw29A retrospective study on DFUs demonstrating favorable healing trends over standard of care using Membrane Wrap™. Journal of Diabetes and Treatment.
doi.org/10.29011/2574-7568.010149A retrospective study spanning DFUs, VLUs, pressure injuries and open wounds, evaluating wound closure and area reduction using Membrane Wrap - Hydro™. Journal of Wound Care.
doi.org/10.12968/jowc.2025.0604A study of the clinical effects of cold plasma using terraplasma medical™’s device: a comparison of the terraplasma medical device with standard of care against standard of care alone. The protocol is being completed and fall enrollment is expected.
™
